pha-022121
Small moleculeexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Feb 3, 2021 (NCT04618211)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Bradykinin B2 receptorINHIBITOR
BDKRB2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05396105 | Phase 2/Phase 3 (Phase 3) | Jul 19, 2022 | Humboldt University, Pharvaris Netherlands B.V. |
| NCT05047185 | Phase 2 | Nov 30, 2021 | J. W. Goethe University, Pharvaris Netherlands B.V., University of California, San Diego |
| NCT04618211 | Phase 2 | Feb 3, 2021 | Humboldt University, Pharvaris Netherlands B.V. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pharvaris Netherlands B.V. | For profit | 3 | 3 | 2 | 2021 |
| Humboldt University | Academic/Hospital | 2 | 0 | 2 | 2021 |
| J. W. Goethe University | Academic/Hospital | 1 | 0 | 1 | 2021 |
| University of California, San Diego | Academic/Hospital | 1 | 0 | 1 | 2021 |
4 organizations
Page 1 / 1